Fig. 2

Potent antitumor activity of DOX@3D-MPs. a, e Schematic timeline for the in vivo pharmacodynamic experiments in subcutaneous H22 (a) and orthotopic 4T1 tumor-bearing mice (e) after administration of six doses of PBS, 3D-MPs, DOX, 3D-MPs+DOX, DOX@3D-MPs derived from H22 TRCs and 4T1 TRCs at DOX dosage of 0.75 mg kg⁻¹ once every other day, respectively, or three doses of high dosage of Doxil at 4 mg kg⁻¹ once every 3 days via tail vein. b, f Tumor volume curves of H22 (b) and 4T1 tumor-bearing mice (f) after treatments indicated in (a, e), respectively. (n = 10 mice in each group). c, g Kaplan-Meier survival curves of H22 (c) and 4T1 tumor-bearing mice (g) after treatments indicated in a and e, respectively (n = 10 mice in each group). d Tumor growth curves of naive mice or DOX@3D-MPs-cured mice indicated in (a) after the second inoculation with H22 cells (2 × 10⁶ cells). (n = 10 for naive mice, n = 2 for DOX@3D-MPs-cured mice). h In vivo bioluminescence images monitoring the growth and spreading of intravenously inoculated 4T1-Luc cells in orthotopic 4T1 tumor-bearing mice after treatments indicated in (e). i Ex vivo bioluminescence images of lung metastatic nodes at 40 days after treatments indicated in (e). j Numbers of lung metastatic nodes of 4T1 tumor-bearing mice at 40 days after treatments indicated in (e). (n = 5 mice in each group). k Representative H&E staining images of the metastatic lungs at 40 days after treatments indicated in (e). Scale bar: 2 mm. Data are shown as means ± s.d. *P < 0.05, ***P < 0.001